Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia

The loss of patentability of many originator biologics has led to the rapid introduction of biosimilar agents. The anticipated economic benefit of introducing such agent has been accompanied by vagueness surrounding their biotechnology, approval requirements, positioning in treatment paradigms and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Saudi Pharm J
Autors principals: Omair, Mohammed A., Alhawassi, Tariq, Alwaihibi, Munira, Aldrees, Ghada, Mosli, Mahmoud, Asser, Wesam M., Alharaibi, Maryam A., Alotaibi, Atheer T., Bintaleb, Doaa A., Alharbi, Najah K., Alotaibi, Ahmed Z., Alshammari, Wajed A., Alanazi, Nouf, Asiri, Ali M., Almadany, Rana, Al Rayes, Hanan, Al-Thunian, Turki, Alotaibi, Moureq, Al Jazaeri, Abdulrazaq
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783213/
https://ncbi.nlm.nih.gov/pubmed/33424270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2020.11.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars